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SUMMARY 
 
Background: Single nucleotide polymorphisms (SNPs) within the transcription factor 7-like 2 (TCF7L2) gene are 
well known risk variants for type 2 diabetes mellitus (T2DM). The association between TCF7L2 SNPs and T2DM 
has been investigated in several studies, but the results are controversial. In this study, we investigated whether 
the rs7903146, rs12255372, and rs290487 polymorphisms of TCF7L2 are associated with T2DM per se or metabol-
ic traits related to this disease in a Kurdish ethnic group of Iran. 
Methods: In all, 173 patients with T2DM and 173 normoglycemic subjects were included in this study. All subjects 
were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Geno-
typic and allelic frequencies were then analyzed in each group. Serum lipids, fasting glucose, fasting serum insu-
lin, HOMA-IR, and HbA1c levels were determined by conventional methods. 
Results: T-allele and genotype frequencies of rs7903146, rs12255372, and rs290487 were significantly different be-
tween T2DM and control subjects. The CT genotype (OR = 1.98, p = 0.008), TT genotype (OR = 3.54, p = 0.024), 
and the dominant model (OR = 2.16, p = 0.002) of rs7903146 were associated with T2DM. The GT genotype (OR = 
2.23, p = 0.005), TT genotype (OR = 4.25, p = 0.046), and the dominant model (OR = 2.2, p = 0.001) of rs12255372 
gave a higher risk for T2DM. The carriers of CT genotype of rs290487 showed a significantly increased risk for 
T2DM (OR = 2.24, p = 0.003). Similarly, the dominant model of this SNP was found to be significantly associated 
with T2DM (OR = 2.25, p = 0.002). The control subjects carrying the T-allele of rs7903146 had higher levels of to-
tal cholesterol (CC; 4.52 ± 1.03 vs. CT + TT; 5.00 ± 1.2 mmol/L, p = 0.009) than those with CC genotype. Normo-
glycemic subjects carrying GT + TT genotypes of rs12255372 had a significantly higher WHR (GG; 0.90 ± 0.059 
vs. GT + TT; 0.93 ± 0.07, p = 0.038) as compared with those with the GG genotype. 
Conclusions: The T-allele of rs12255372, rs7903146, and rs290487 polymorphisms of TCF7L2 confer susceptibility 
to T2DM in the Kurdish population of Iran. 
(Clin. Lab. 2014;60:1269-1276. DOI: 10.7754/Clin.Lab.2013.130809) 
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INTRODUCTION 
 
Diabetes mellitus (DM) is a chronic metabolic disorder 
characterized by an elevated blood glucose level that is 
caused by defects in insulin secretion, insulin action, or 
both [1]. Today, 366 million people have diabetes 
worldwide, and the number is predicted to reach 552 
million by 2030 [2]. Type 2 diabetes mellitus (T2DM) 
is the most common form of diabetes characterized by 
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insulin resistance with a relative or real insulin deficien-
cy [3]. Over the past 3 - 4 decades, the global preva-
lence of T2DM has dramatically increased [1]. The ex-
act cause for the current rise is not yet clearly known; 
however, genetic variations as well as environmental 
factors play a part in the development of T2DM [4]. Ge-
netic susceptibility appears to have a crucial role in the 
etiology and manifestation of the disease [5,6]. 
The TCF7L2 gene is located on chromosome 10q25.3 
(114700201–114916063, NCBI build 36.2) [7]. Several 
SNPs of the TCF7L2 gene are well known risk variants 
for T2DM [8]; however, the mechanism by which these 
variations predispose to T2DM is not exactly known. It 
has been suggested that TCF7L2 encodes a transcription 
factor that is expressed in the fetal pancreas and in-
volved in the Wnt signaling pathway through regulating 
glucagon-like peptide (GLP-1), which, in addition to in-
sulin, has a primary role in blood glucose homeostasis 
[9,10]. The risk SNPs of TCF7L2 for T2DM include: 
rs7903146 (C/T), rs12255372 (G/T), and rs290487 
(C/T). In recent years, the association between the SNPs 
of TCF7L2 mentioned and T2DM has been demonstrat-
ed in various ethnic groups [11-18], but the findings 
have been inconsistent in some populations [19-21]. 
To our knowledge, because the relationship between 
SNPs rs7903146, rs12255372, and rs290487 of TCF7L2 
and T2DM in the Kurdish ethnic group of Iran have not 
been addressed yet and the controversial results from 
other populations, we aimed to explore the possible as-
sociation between these TCF7L2 variants and T2DM 
and its metabolic quantitative traits in a sample of the 
Iranian Kurdish ethnic group. To these ends, we exam-
ined the allele and genotype frequencies of the above 
polymorphisms in T2DM and non-T2DM subjects, and 
detected their effects on anthropometric, diabetes, and 
obesity related parameters. 
 
 
MATERIALS AND METHODS 
 
Subjects and protocols 
The protocol of this study was approved by the ethics 
committee of Ilam University of Medical Science, Iran 
(No: EC/92/H/131). The study population included 173 
(males/females: 82/91; age: 54.97 ± 11.01 years) Irani-
an unrelated patients with type 2 diabetes and 173 
(males/females: 73/100; age: 50.29 ± 9.64 years) Irani-
an unrelated healthy controls. All subjects originated 
from the Ilam and Kermanshah provinces situated in the 
west of Iran and belonged to the Kurdish ethnic group. 
Diabetic and healthy controls were distinguished based 
on their glycemic status, which was defined according 
to WHO 1997 criteria [22]. The control group only con-
tained individuals with a normal fasting glucose level 
and negative family history of type 2 diabetes among 
first-degree relatives. The written informed consent was 
obtained from all participants before enrollment in the 
study. 
Screening included standardized questionnaires on per-
sonal data and clinical measurements such as age, gen-
der, obesity, drug consumption during the past month, 
and medical or family history of diabetes [23]. All those 
who were not taking diabetes medication underwent a 2 
hours oral glucose tolerance test (OGTT) after an over-
night fast. Criteria for control selection were fasting 
glucose < 6.1 mmol/L and 2 hours plasma glucose < 7.8 
mmol/L after OGTT. Diabetes was defined as fasting 
glucose ≥ 7.0 mmol/L, 2 hours glucose ≥ 11.1 mmol/L 
after OGTT, or use of hypoglycemic medication. Systo-
lic and diastolic blood pressure was measured twice in 
the right arm of the subjects who had been resting for at 
least 10 minutes in a comfortable position. Signed in-
formed consent was obtained from all subjects, and the 
study was approved by the Institutional Ethics Commit-
tee. All participants were interviewed to obtain clinical 
data and type 2 diabetes mellitus family histories. BMI 
was estimated through dividing weight in kilograms by 
the height in meters squared. Insulin resistance was as-
sessed from glucose and insulin concentrations using 
the homeostasis model assessment of insulin resistance 
(HOMA-IR) equation [24]. 
 
Sample preparation 
Blood samples were collected from patients and con-
trols in the morning, after an overnight (12 - 14 hours) 
fasting. 5 mL of venous blood was withdrawn from the 
antecubital vein into Vacutainer tubes containing EDTA 
as the anticoagulant. To separate plasma, blood samples 
were centrifuged at 3000 rpm for 10 minutes. Superna-
tant was used for biochemical experiments, and the 
Buffy coat and red blood cell pellet were used for DNA 
extraction. 
 
Biochemical assays 
Serum blood glucose, triglycerides, total cholesterol, 
LDL-C and HDL-C levels were measured by the stan-
dard enzymatic method (Pars Azmon kit, Iran), using 
the auto analyzer system BT3000 (Biotechnica, Italy). 
Serum concentrations of insulin were assessed using an 
ELISA kit specific for human insulin according to the 
manufacturer's instructions (Monobind Inc., USA). 
 
Genotyping 
Leukocyte genomic DNA was extracted from the blood 
specimen using the standard procedure involving pro-
teinase K and phenol/chloroform. 
The TCF7L2 rs7903146 polymorphic site (C/T) was 
amplified by the polymerase chain reaction (PCR) 
method using the primer pair 5´-TTAGAGAGCTAAG 
CACTTTTTAGGTA-3´ (forward) and 5´-GTTACTTG 
CCTTCCCTGTA ACTG-3´ (reverse). PCR was per-
formed in a final volume of 25 µL containing 100 ng 
genomic DNA, 1.5 mmol/L MgCl2, 0.5 mmol/L of each 
dNTPs, and 0.5 pmol of each primer. After an initial de-
naturation of 2 minutes at 94°C, the samples were sub-
jected to 30 cycles at 94°C for 1 minute, 55°C for 40 
seconds, and 72°C for 30 seconds, with a final exten-
sion of 10 minutes at 72°C. The 102-bp product was di-
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gested with restriction enzyme RsaI for 8 hours at 37°C 
followed by agarose gel electrophoresis. The digested 
products were stained with ethidium bromide. T-allele 
was not cleaved by RsaI and gave a 102-bp band, and 
C-allele was cleaved into two bonds 77- and 25-bp. The 
fragment containing the rs12255372 polymorphic site 
(G/T) was amplified using the primer pair 5´-AGGAAT 
ATCCAGGCAAGCAT-3´ (forward) and a reverse 
primer of 5´-CTGGCACTCAGAAGAGAGTCAG-3´ 
(reverse). 
PCR conditions were the same as for rs7903146, except 
the annealing temperature was 61°C. The PCR product 
was electrophoresed on polyacrylamide gel and stained 
with ethidium bromide. The 99-bp product was digested 
with restriction enzyme NlaIII for 7 hours at 37°C fol-
lowed by agarose gel electrophoresis. The digested 
products were stained with ethidium bromide. The T-al-
lele was not cleaved by NlaIII and gave a 102-bp band, 
and the G-allele was cleaved into two bonds 78- and 21-
bp. 
The TCF7L2 rs290487 polymorphic site (C/T) was am-
plified by the polymerase chain reaction (PCR) method 
using the primer pair 5´-AGGAGGCTGCCATATTGT 
TACTT-3´ (forward) and 5´-ACACCTTTCTCATTTT 
CAATTTCGC-3´ (reverse). PCR conditions were the 
same as for rs7903146, except the annealing tempera-
ture was 63°C. The PCR product was digested with the 
restriction enzyme AccII at 37°C for 7 hours followed 
by agarose gel electrophoresis. The C-allele was not 
cleaved by BtsI and gave a 153-bp band and the T-allele 
was cleaved into two bonds 128- and 25-bp. 
 
Statistical analysis 
All statistical analyses were carried out using the statis-
tical program SPSS (version 19, SPSS, Chicago, IL, 
USA); Differences in genotype/allele frequencies were 
compared by the Chi-square test or Fisher’s exact test 
where appropriate. 
One-way analysis of variance (ANOVA) was utilized to 
compare the clinical features among groups with differ-
ent genotypes. Odds ratios (ORs) and 95% CI were cal-
culated by logistic regression analysis using diabetes as 
a dependent variable and the genotypes as independent 
variables. 
We used the Pearson’s goodness-of-fit chi-square (χ2) 
test to evaluate the deviation from Hardy-Weinberg 
equilibrium. Armitage's trend test was applied to assess 
for the presence of association between different groups 
of genotypes. Other genetic models including dominant, 
recessive and multiplicative models were also consid-
ered to analyze SNP association [25]. 
Baseline quantitative results were expressed as mean ± 
standard deviation (SD) and compared with the Stu-
dent’s t test; the continuous variables that failed the nor-
mality test were logarithmically transformed before 
analysis. The variables transformed were triglyceride, 
insulin, and HOMA-IR. Statistical differences are based 
on analyses of log-transformed data, but means of un-
transformed data are presented in tables. 
RESULTS 
 
The clinical, anthropometrical, and biochemical charac-
teristics of the participants are shown in Table 1. Gen-
der distribution was almost same in T2DM patients and 
their controls. The mean of age in T2DM patients and 
the control group was 54.98 ± 11.1 and 53.3 ± 9.7, res-
pectively. All characteristics of the participants differed 
significantly between T2DM and normoglycemic con-
trol (p < 0.05). T2DM subjects had significantly higher 
values for BMI, triglyceride, HbA1c, glucose, total cho-
lesterol, waist to hip ratio, LDL-C, HOMA-IR, diastolic 
and systolic blood pressure and insulin, and lower levels 
of HDL-C than normoglycemic control subjects (p < 
0.05). 
The genotype distribution and relative allele frequencies 
of rs7903146 (C/T), rs12255372 (G/T), and rs290487 
(C/T) polymorphisms at the TCF7L2 gene in the study 
subjects are showed in Table 2. All three variants were 
in Hardy-Weinberg equilibrium in T2DM (χ2 = 2.16,   
df = 1, p = 0.143 for rs7903146; χ2 = 1.10, df = 1,         
p = 0.294 for rs12255372; χ2 = 2.28, df = 1, p = 0.132 
for rs290487) and control subjects (χ2 = 0.423, df = 1,   
p = 0.52 for rs7903146CT; χ2 = 1.058, df = 1, p = 0.304 
for rs12255372GT ; χ2 = 3.31, df = 1, p = 0.069 for 
rs290487). 
The corresponding risk associated with different geno-
types of each SNP is shown in Table 2. The distribution 
of the T-allele of rs7903146 was meaningfully (p = 
0.000) higher in the T2DM subjects than in the control 
subjects (27% vs. 15%, respectively). The frequencies 
of genotypes CT and TT of this SNP also significantly 
differed between the study groups (p = 0.008 and 0.024, 
respectively). The CT genotype (OR = 1.98, 95% CI = 
1.2 - 3.28, p = 0.008), TT genotype (OR = 3.54, 95% CI 
= 1.18 - 10.53, p = 0.024) and the dominant model (OR 
= 2.16, 95% CI = 1.34 - 3.48, p = 0.002) of rs7903146 
were associated with T2DM after adjustment for age, 
gender, and BMI. 
The frequency of the T-allele of rs12255372 variant was 
significantly (0.001) higher in the T2DM subjects com-
pared with the control subjects (18% vs. 10%, respec-
tively). Also, the distribution of genotypes GT and TT 
of this SNP were significantly higher in the T2DM sub-
jects than in the control subjects (p = 0.005 and 0.046, 
respectively). After adjustment for age, gender, and 
BMI, the GT genotype (OR = 2.23, 95% CI = 1.28 - 
3.88, p = 0.005), TT genotype (OR = 4.25, 95% CI = 
1.03 - 17.61, p = 0.046), and the dominant model (OR = 
2.2, 95% CI = 1.41 - 4.08, p = 0.001 of rs12255372 
gave a higher risk for T2DM. 
The T-allele of the rs290487 variant was significantly 
(0.002) different between study groups with the higher 
occurrence in the T2DM subjects than the control sub-
jects (22% vs. 14%). The CT genotype of this SNP was 
more significantly frequent in T2DM subjects than the 
control subjects (p = 0.003). The carriers of the CT ge-
notype of rs290487 variant showed a significantly in-
creased risk for T2DM (OR = 2.24, 95%, CI = 1.32 -       
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Table 1. Anthropometrical, clinical, and biochemical characteristics of the study groups. 
 
 Groups  
Characteristics T2DM Control P-value 
Number of individuals (male/female) 173 (73/100) 173 (82/91) - 
Age (year) 54.98 ± 11.1 53.3 ± 9.7 0.134 
BMI (kg/m2) 28.8 ± 4.86 26.9 ± 4.32 0.000 
WHR 0.94 ± 0.07 0.91 ± 0.062 0.000 
FPG (mmol/L) 9.18 ± 2.75 5.29 ± 0.57 0.000 
HbA1c (%) 8.13 ± 1.72 5.02 ± 0.35 0.000 
TG (mmol/L) 2.07 ± 0.47 1.65 ± 0.46 0.000 
TC (mmol/L) 5.13 ± 1.06 4.65 ± 1.1 0.000 
HDL-C (mmol/L) 0.93 ± 0.25 2.99 ± 0.69 0.000 
LDL-C (mmol/L) 3.41 ± 0.94 3.04 ± 0.8 0.000 
SBP (mm Hg) 13.1 ± 1.85 11.86 ± 1.07 0.000 
DBP (mm Hg) 8.46 ± 1.31 8.0 ± 0.95 0.000 
FPI (µIU/mL) 9.9 ± 3.41 7.33 ± 2.08 0.000 
HOMA-IR 3.98 ± 1.77 1.72 ± 0.5 0.000 
 
Data are presented as mean ± SD. P-values < 0.05 are considered as significant. BMI - body mass index, WHR - waist to hip ratio, FPG - 
fasting plasma glucose, HbA1c - hemoglobin A1c, TG - triglyceride, TC - total cholesterol, HDL-C - high-density lipoprotein cholesterol,   
LDL-C - low-density lipoprotein cholesterol, SBP - systolic blood pressure, DBP - diastolic blood pressure, FPI - fasting plasma insulin, 
HOMA-IR - homeostasis model assessment-insulin resistance. 
 
 
 
 
3.82, p = 0.003). Similarly, the dominant model of this 
SNP was found to be significantly associated with 
T2DM (OR = 2.25, 95% CI = 1.36 - 3.71, p = 0.002). 
We classified the clinical and biochemical characteris-
tics of the study subjects according to the dominant 
model of rs7903146, rs12255372, and rs290487 (Table 
3, 4, and 5, respectively). Table 3 shows the characteris-
tics of the study subjects categorized according to the 
dominant model for rs7903146. As shown in this table, 
T2DM subjects carrying the CT + TT genotypes of this 
variation had no significant difference in any variables 
as compared with those with the CC genotype. When 
comparing the clinical and biochemical features of con-
trol subjects with the T-allele and those without, it was 
found that subjects carrying the T-allele of rs7903146 
had higher levels of total cholesterol (CC; 4.52 ± 1.03 
vs. CT + TT; 5.00 ± 1.2 mmol/L, p = 0.009). 
Table 4 presents the clinical and biochemical character-
istics of the study subjects categorized according to the 
dominant model of rs12255372. As shown in this table, 
normoglycemic subjects carrying the GT + TT geno-
types of this variation had a significantly higher WHR 
(GG; 0.90 ± 0.059 vs. GT + TT; 0.93 ± 0.07, p = 0.038) 
as compared with those with the GG genotype. In 
T2DM subjects, no significant difference was found in 
any of the clinical or biochemical parameters between 
GG and GT + TT genotypes of rs12255372. 
As shown in Table 5, among the T2DM and normogly-
cemic control subjects, there was no significant differ-
ence in any of the clinical or biochemical parameters 
between the CC and CT + TT genotypes of the 
rs290487. 
 
 
DISCUSSION 
 
One commonly used approach to define the genetic pre-
disposition of T2DM is the candidate gene approach. 
This approach focuses on the search for an association 
between T2DM and sequence variants in or near biolog-
ically defined candidate genes which have been chosen 
based on their known physiological function. The im-
portance of these variants or other nearby variants is 
tested by comparing the frequency in T2DM patients 
and normal glucose tolerant subjects [23,26,27]. Among 
all identified variants, the TCF7L2 genetic variants have 
the largest effect on the risk of type 2 diabetes [28]. 
However, the role of the TCF7L2 polymorphism in type 
2 diabetes in the Kurdish ethnic group of Iran remains 
uncertain. The contribution of TCF7L2 variants to 
T2DM risk has been confirmed in some [11-18], but not 
all, populations studied so far [19-21]. In this study, we 
examined the association of rs7903146, rs12255372, 
and rs290487 in the TCF7L2 gene with T2DM and re-
lated metabolic traits using a case-control method. We 
selected these SNPs due to their previous association 
with T2DM [11-18]. Based on our findings, there is an 
association between the T-allele and genotypes of          
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Table 2. The genotype/allele status and associated risk for T2DM in the study groups. 
 
P-value OR (95% CI) 
Groups 
Genotype/Allele SNP 
T2DM Control 
Reference 1 97 126 CC 
rs7903146 
0.008 1.98 (1.2 - 3.28) 60 42 CT 
0.024 3.54(1.18 - 10.53) 16 5 TT 
0.002 2.16 (1.34 - 3.48)   CC vs. CT + TT 
0.055 2.88 (0.98 - 8.5)   CC + CT vs. TT 
  0.73 0.85 C 
0.000 2.05 (1.40 - 3.0) 0.27 0.15 T 
Reference 1 117 141 GG 
rs12255372 
0.005 2.23 (1.28 - 3.88) 48 29 GT 
0.046 4.25 (1.03 - 17.61) 8 3 TT 
0.001 2.4 (1.41 - 4.08)   GG vs. GT + TT 
0.083 3.48 (0.85 - 14.24)   GG + GT vs. TT 
  0.82 0.90 C 
0.001 2.02 (1.3 - 3.13) 0.18 0.10 T 
Reference 1 108 132 CC 
rs290487 
0.003 2.24 (1.32 - 3.82) 53 35 CT 
0.134 2.3 (0.78 - 6.79) 12 6 TT 
0.002 2.25 (1.36 - 3.71)   CC vs. CT + TT 
0.267 2.83 (0.63 - 5.34)   CC + CT vs. TT 
  0.78 0.86 C 
0.002 1.82 (1.23 - 2.71) 0.22 0.14 T 
 
All data adjusted based on age, gender, and BMI. 
P-values < 0.05 are considered as significant. 
 
 
 
 
Table 3. Clinical and biochemical characteristics of the study subjects according to the dominant model of rs7903146. 
 
 Type 2 diabetic subjects Control subjects 
Characteristics CC (97) CT + TT (76) P-value CC (126) CT + TT (47) P-value 
BMI (kg/m2) 28.65 ± 5.04 28.99 ± 4.64 0.651 24.23 ± 3.13 23.74 ± 3.71 0.106 
WHR 0.94 ± 0.06 0.93 ± 0.07 0.494 0.91 ± 0.06 0.90 ± 0.063 0.438 
FPG (mmol/L) 9.31 ± 2.92 9.02 ± 2.53 0.496 5.30 ± 0.58 5.26 ± 0.54 0.746 
HbA1c (%) 8.22 ± 1.86 8.02 ± 1.53 0.443 5.04 ± 0.35 4.96 ± 0.36 0.141 
TG (mmol/L) 2.08 ± 0.47 2.06 ± 0.48 0.828 1.69 ± 0.46 1.54 ± 0.45 0.058 
TC (mmol/L) 5.63 ± 1.05 5.55 ± 1.07 0.157 4.52 ± 1.03 5.00 ± 1.2 0.019 * 
HDL-C (mmol/L) 0.97 ± 0.24 0.89 ± 0.25 0.051 2.99 ± 0.69 2.99 ± 0.70 0.966 
LDL-C (mmol/L) 3.5 ± 0.91 3.3 ± 0.96 0.177 1.97 ± 0.78 2.05 ± 0.81 0.889 
SBP (mm Hg) 12.98 ± 1.67 13.25 ± 2.06 0.343 11.95 ± 1.13 11.60 ± 0.86 0.053 
DBP (mm Hg) 8.39 ± 1.23 8.56 ± 1.41 0.375 8.02 ± 0.96 7.96 ± 0.94 0.719 
FPI (µIU/mL) 10.14 ± 3.76 9.61 ± 2.90 0.309 7.41 ± 2.14 7.12 ± 1.92 0.410 
HOMA-IR 4.17 ± 2.03 3.75 ± 1.33 0.117 1.74 ± 0.52 1.65 ± 0.44 0.322 
 
Data are presented as mean ± SD. * - P-values < 0.05. Abbreviations are same as Table 1. 
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Table 4. Clinical and biochemical characteristics of the study subjects according to the dominant model of rs12255372. 
 
 Type 2 diabetic subjects Control subjects 
Characteristics GG (117) GT + TT (56) P-value GG (141) GT + TT (32) P-value 
BMI (kg/m2) 29.12 ± 4.94 28.13 ± 4.65 0.213 24.15 ± 4.42 23.84 ± 3.69 0.121 
WHR 0.94 ± 0.59 0.94 ± 0.82 0.869 0.90 ± 0.059 0.93 ± 0.07 0.038 * 
FPG (mmol/L) 9.19 ± 2.81 9.15 ± 2.63 0.931 5.29 ± 0.58 5.25 ± 0.54 0.720 
HbA1c (%) 8.30 ± 1.75 7.79 ± 1.60 0.065 5.02 ± 0.36 4.99 ± 0.32 0.609 
TG (mmol/L) 2.10 ± 0.46 2.0 ± 0.50 0.263 1.65 ± 0.44 1.65 ± 0.54 0.911 
TC (mmol/L) 5.67 ± 1.05 5.54 ± 1.09 0.211 4.25 ± 1.09 4.14 ± 1.1 0.542 
HDL-C (mmol/L) 0.95 ± 0.25 0.91 ± 0.24 0.323 3.01 ± 0.69 2.93 ± 0.71 0.536 
LDL-C (mmol/L) 3.49 ± 0.97 3.25 ± 0.86 0.107 2.07 ± 0.93 1.88 ± 0.80 0.084 
SBP (mm Hg) 13.08 ± 1.85 13.14 ± 1.86 0.839 11.86 ± 1.09 11.85 ± -0.99 0.959 
DBP (mm Hg) 8.44 ± 1.25 8.51 ± 1.44 0.731 7.69 ± 0.93 8.06 ± 1.02 0.302 
FPI (µIU/mL) 9.74 ± 3.46 10.26 ± 3.31 0.343 7.38 ± 2.10 7.13 ± 1.98 0.534 
HOMA-IR 3.96 ± 1.92 4.04 ± 1.41 0.760 1.73 ± 0.52 1.65 ± 0.43 0.399 
 
Data are presented as mean ± SD. * - P-values < 0.05. Abbreviations are same as Table 1. 
 
 
 
 
Table 5. Clinical and biochemical characteristics of the study subjects according to the dominant model of rs290487. 
 
 Type 2 diabetic subjects Control subjects 
Characteristics GG (108) GR + RR (65) P-value GG (132) GR+RR (41) P-value 
BMI (kg/m2) 28.94 ± 5.38 28.56 ± 3.87 0.615 23.91 ± 2.11 24.09 ± 2.98 0.183 
WHR 0.93 ± 0.068 0.94 ± 0.066 0.408 0.91 ± 0.63 0.91 ± 0.58 0.592 
FPG (mmol/L) 9.16 ± 3.03 9.21 ± 2.22 0.904 5.3 ± 0.57 5.23 ± 0.57 0.514 
HbA1c (%) 8.14 ± 1.81 8.12 ± 1.56 0.949 5.02 ± 0.32 5.01 ± 0.44 0.949 
TG (mmol/L) 2.04 ± 0.47 2.13 ± 0.48 0.203 1.63 ± 0.46 1.72 ± 0.47 0.272 
TC (mmol/L) 5.07 ± 1.13 5.23 ± 0.93 0.336 4.34 ± 1.10 4.25 ± 1.08 0.794 
HDL-C (mmol/L) 0.94 ± 0.25 0.92 ± 0.24 0.614 2.98 ± 0.69 3.03 ± 0.68 0.680 
LDL-C (mmol/L) 3.43 ± 0.93 3.38 ± 0.96 0.739 2.00 ± 0.82 2.17 ± 0.91 0.235 
SBP (mm Hg) 13.02 ± 1.87 12.73 ± 1.78 0.145 11.91 ± 1.06 11.68 ± 1.12 0.213 
DBP (mm Hg) 8.65 ± 1.37 8.72 ± 1.19 0.287 8.00 ± 0.98 7.98 ± 0.86 0.851 
FPI (µIU/ml) 10.26 ± 3.75 9.32 ± 2.67 0.080 7.37 ± 2.13 7.22 ± 1.91 0.692 
HOMA-IR 4.99 ± 1.96 3.79 ± 1.37 0.253 1.73 ± 0.51 1.68 ± 0.46 0.555 
 
Data are presented as mean ± SD. * - P values < 0.05. Abbreviations are same as Table 1. 
 
 
 
 
rs7903146, rs12255372, and rs290487 variants and 
T2DM. In a Japanese study, four SNPs of TCF7L2 
(rs12255372, rs7903146, rs7901695, and rs11196205) 
were investigated and all four SNPs were found to be 
significantly associated with T2DM, with rs12255372 
showing the strongest association [30]. An Indian study 
explored rs7903146, rs12255372, and rs4506565 of 
TCF7L2 and reported a significant association between 
all three SNPs and T2DM [29]. A study was conducted 
on Moroccans [31] and significant association between 
rs7903146 variant of TCF7L2 and T2D risk in this pop-
ulation was concluded. Furthermore, a positive associa-
tion was also reported on Indian Asians [32,33], Paki-
stanis [34], and Afro-Caribbeans. A study that was done 
in the Polish population showed that the TT genotype 
was associated with type 2 diabetes. The increased risk 
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of type 2 diabetes was not observed for the CT geno-
type. A trend was found, but the results for the CT ge-
notype were not significant [35]. The rs7903146 SNP of 
the TCF7L2 gene is associated with increased suscepti-
bility to T2DM in the Chinese population [3]. Further-
more, research in a clinical trial that was conducted at 
27 centers in the United States found that common var-
iants in TCF7L2 (rs7903146 and rs12255372) seem to 
be associated with an increased risk of diabetes among 
persons with impaired glucose tolerance [39]. Recently, 
three independent studies in non-European populations 
including Chinese [14], Pima Indians [37], and Emirati 
Arabs [38] failed to find any association between 
TCF7L2 variants and T2DM. Also in a study that was 
conducted in the Arab population showed a weak or no 
association of T2DM with the two TCF7L2 variants 
(rs7903146 and rs12255372) [19]. 
Compared with CT + TT genotypes, the CC genotype 
of rs7903146 was significantly associated with the low-
er levels of total cholesterol in control subjects. To our 
knowledge, this has not been previously reported. In 
Tuscany, Italy, the TCF7L2 rs7903146 polymorphism 
was associated with lower insulin levels, smaller waist 
circumference, and lower risk lipid profiles in the gen-
eral elderly population. Patients with diabetes who are 
carriers of the minor allele are less likely to have meta-
bolic-syndrome features [36]. The reason for the appar-
ent discrepancies between the studies, including ours, 
can be attributed to several factors such as the study de-
sign, sample size, population heterogeneity, and gene-
environment interactions [23,27]. 
We also found that normoglycemic subjects carrying 
the GT + TT genotypes of the rs12255372 variation had 
a significantly higher WHR as compared with those 
with the GG genotype. This result is in accordance with 
the previously reported findings [40]. Based on our 
findings, among the T2DM and normoglycemic control 
subjects, there was no significant difference in any of 
the clinical or biochemical parameters between the CC 
and CT + TT genotypes of rs290487. To our knowl-
edge, there is no published report for this association so 
far. 
In conclusion, this is the first study performed in the 
Kurdish ethnic group from West Iran, in which a signif-
icance of genetic variations of the TCF7L2 gene was in-
vestigated in the pathogenesis of T2DM. The findings 
of our study revealed that rs7903146, rs12255372, and 
rs290487 polymorphisms of TCF7L2 are associated 
with the risk of T2DM. 
 
 
Acknowledgement: 
This project was supported financially by the deputy for 
research and technology of Ilam University of Medical 
Sciences. 
 
 
Declaration of Interest: 
The authors have no competing interests to declare. 
References: 
 
1. Alhyas L, McKay A, Majeed A. Prevalence of type 2 diabetes in 
the States of the co-operation council for the Arab States of the 
Gulf: a systematic review. PLoS One 2012;7:e40948. 
 
2. Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and can-
cer risk: review of the epidemiological evidence. Cancer Sci 
2013;104:9-14. 
 
3. Wang J, Hu F, Feng T, et al. Meta-analysis of associations be-
tween TCF7L2 polymorphisms and risk of type 2 diabetes melli-
tus in the Chinese population. BMC Med Genet 2013;12:8-14. 
 
4. O'Rahilly S, Barroso I, Wareham NJ. Genetic factors in type 2 
diabetes: the end of the beginning? Science 2005;307:370-3. 
 
5. Flores-Martinez S.E, Islas-Andrade S, Machorro-Lazo MV, et al. 
DNA polymorphism analysis of candidate genes for type 2 diabe-
tes mellitus in a Mexican ethnic group. Ann Genet 2004;47:339-
48. 
 
6. Radha V, Mohan V. Genetic predisposition to type 2 diabetes 
among Asian Indians. Indian J Med Res 2007;125:259-74. 
 
7. Duval A, Busson-Leconiat M, Berger R, Hamelin R. Assignment 
of the TCF-4 gene (TCF7L2) to human chromosome band 
10q25.3. Cytogenet Cell Genet 2000;88:264-5. 
 
8. Heni M, Herzberg-Schafer S, Machicao F, Haring HU, Fritsche 
A. Dietary fiber intake modulates the association between vari-
ants in TCF7L2 and weight loss during a lifestyle intervention. 
Diabetes Care 2012;35:e24. 
 
9. Tangjittipokin W, Chongjarean N, Plengvidhya N, Homsanit M, 
Yenchitsomanus PT. Transcription factor 7-like 2 (TCF7L2) vari-
ations associated with earlier age-onset of type 2 diabetes in Thai 
patients. J Genet 2012;91:251-5. 
 
10. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 
2007;87:1409-39. 
 
11. Barra GB, Dutra LA, Watanabe SC, et al. Association of the 
rs7903146 single nucleotide polymorphism at the Transcription 
Factor 7-like 2 (TCF7L2) locus with type 2 diabetes in Brazilian 
subjects. Arq Bras Endocrinol Metabol 2012;56:479-84. 
 
12. Berhouma R, Kouidhi S, Ammar M, et al. Genetic susceptibility 
to type 2 diabetes: a global meta-analysis studying the genetic 
differences in Tunisian populations. Hum Biol 2012;84:423-35. 
 
13. Buraczynska M, Swatowski A, Markowska-Gosik D, Kuczma-
szewska A, Ksiazek A. Transcription factor 7-like 2 (TCF7L2) 
gene polymorphism and complication/comorbidity profile in type 
2 diabetes patients. Diabetes Res Clin Pract 2011;93:390-5. 
 
14. Chang YC, Chang TJ, Jiang YD, et al. Association study of the 
genetic polymorphisms of the transcription factor 7-like 2 
(TCF7L2) gene and type 2 diabetes in the Chinese population. 
Diabetes 2007;56:2631-7. 
 
15. Liu PH, Chang YC, Jiang YD, et al. Genetic variants of TCF7L2 
are associated with insulin resistance and related metabolic phe-
notypes in Taiwanese adolescents and Caucasian young adults. J 
Clin Endocrinol Metab 2009;94:3575-82. 
 
16. Nemr R, Turki A, Echtay A, et al. Transcription factor-7-like 2 
gene variants are strongly associated with type 2 diabetes in Leb-
anese subjects. Diabetes Res Clin Pract 2012;98:e23-7. 
 
17. Ng MC, Tam CH, Lam VK, So WY, Ma RC, Chan JC. Replica-
tion and identification of novel variants at TCF7L2 associated 
with type 2 diabetes in Hong Kong Chinese. J Clin Endocrinol 
Metab 2007;92:3733-7. 
S. SHOKOUHI et al. 
Clin. Lab. 8/2014 1276
18. Zheng X, Ren W, Zhang S, et al. Association of type 2 diabetes 
susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) 
and proinsulin conversion in a Chinese population. Mol Biol Rep 
2012;39:17-23. 
 
19. Alsmadi O, Al-Rubeaan K, Mohamed G, et al. Weak or no asso-
ciation of TCF7L2 variants with Type 2 diabetes risk in an Arab 
population. BMC Med Genet 2008;9:72. 
 
20. Kahveci C, Koldemir M, Cagatay P, et al. Relationship of tran-
scription factor 7 like 2 gene rs7903146 variation with type 2 dia-
betes and obesity related parameters. Diabetes & Metabolic Syn-
drome: Clinical Research & Reviews 2012;6:48-53. 
 
21. Ren Q, Han XY, Wang F, et al. Exon sequencing and association 
analysis of polymorphisms in TCF7L2 with type 2 diabetes in a 
Chinese population. Diabetologia 2008;51:1146-52. 
 
22. Report of the Expert Committee on the Diagnosis and Classifica-
tion of Diabetes Mellitus. Diabetes Care1997;20:1183-97. 
 
23. Saberi H, Mohammadtaghvaei N, Gulkho S, et al. The ENPP1 
K121Q polymorphism is not associated with type 2 diabetes and 
related metabolic traits in an Iranian population. Mol Cell Bio-
chem 2011;350:113-8. 
 
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher 
DF, Turner RC. Homeostasis model assessment: insulin resis-
tance and beta-cell function from fasting plasma glucose and in-
sulin concentrations in man. Diabetologia 1985;28:412-9. 
 
25. Sasieni PD. From genotypes to genes: doubling the sample size. 
Biometrics 1997;53:1253-61. 
 
26. Whittemore AS. Genome scanning for linkage: an overview. Am 
J Hum Genet 1996;59:704-16. 
 
27. Haghani K, Bakhtiyari S. The study on the relationship between 
IRS-1 Gly972Arg and IRS-2 Gly1057Asp polymorphisms and 
type 2 diabetes in the Kurdish ethnic group in West Iran. Genet 
Test Mol Biomarkers 2012;16:1270-6. 
 
28. Chang YC, Chiu YF, Ho LL, et al. TCF7L2 genetic variants and 
progression to diabetes in the Chinese population: pleiotropic ef-
fects on insulin secretion and insulin resistance. J Mol Med (Berl) 
2010;88:183-92. 
 
29. Chandak GR, Janipalli CS, Bhaskar S, et al. Common variants in 
the TCF7L2 gene are strongly associated with type 2 diabetes 
mellitus in the Indian population. Diabetologia 2007;50:63-7. 
 
30. Hayashi T, Iwamoto Y, Kaku K, Hirose H, Maeda S. Replication 
study for the association of TCF7L2 with susceptibility to type 2 
diabetes in a Japanese population. Diabetologia 2007;50:980-4. 
 
 
31. Cauchi S, El Achhab Y, Choquet H, et al. TCF7L2 is reproduc-
ibly associated with type 2 diabetes in various ethnic groups: a 
global meta-analysis. J Mol Med (Berl) 2007;85:777-82. 
 
32. Bodhini D, Radha V, Dhar M, Narayani N, Mohan V. The 
rs12255372(G/T) and rs7903146(C/T) polymorphisms of the 
TCF7L2 gene are associated with type 2 diabetes mellitus in 
Asian Indians. Metabolism 2007;56:1174-8. 
 
33. Humphries SE, Gable D, Cooper JA, et al. Common variants in 
the TCF7L2 gene and predisposition to type 2 diabetes in UK Eu-
ropean Whites, Indian Asians and Afro-Caribbean men and wo-
men. J Mol Med (Berl) 2006;84:1005-14. 
 
34. Rees SD, Bellary S, Britten AC, et al. Common variants of the 
TCF7L2 gene are associated with increased risk of type 2 diabe-
tes mellitus in a UK-resident South Asian population. BMC Med 
Genet 2008;9:8. 
 
35. Moczulski D, Gawlik B, August R, Strojek K, Grzeszczak W. 
TCF7L2 gene is associated with type 2 diabetes in Polish popula-
tion. Diabetologia Doświadczalna i Kliniczna 2007;7:109-11. 
 
36. Melzer D, Murray A, Hurst AJ, et al. Effects of the diabetes link-
ed TCF7L2 polymorphism in a representative older population. 
BMC Med 2006;4:34. 
 
37. Guo T, Hanson RL, Traurig M, et al. TCF7L2 is not a major sus-
ceptibility gene for type 2 diabetes in Pima Indians: analysis of 
3,501 individuals. Diabetes 2007;56:3082-8. 
 
38. Saadi H, Nagelkerke N, Carruthers SG, et al. Association of 
TCF7L2 polymorphism with diabetes mellitus, metabolic syn-
drome, and markers of beta cell function and insulin resistance in 
a population-based sample of Emirati subjects. Diabetes Res Clin 
Pract 2008;80:392-8. 
 
39. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymor-
phisms and progression to diabetes in the Diabetes Prevention 
Program. N Engl J Med 2006;355:241-50. 
 
40. Alami FM, Ahmadi M, Bazrafshan H, et al. Association of the 
TCF7L2 rs12255372 (G/T) variant with type 2 diabetes mellitus 
in an Iranian population. Genet Mol Biol 2012;35:413-7. 
 
 
Correspondence: 
Salar Bakhtiyari, PhD 
Department of Clinical Biochemistry 
Faculty of Medicine 
Ilam University of Medical Sciences 
Ilam, I.R. Iran 
Tel./Fax:    +98-841-2235745 
Email:      bakhtiyaribio@gmail.com 
      bakhtiyari-s@medilam.ac.ir
 
